Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.64 |
| ▸ | KDR | P35968 | 7/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293257 | 0.88 | EGFR (0.70) | EGFRFGFR1KDRMAPK10MAPK8 | |
| SCHEMBL4968277 | 0.81 | NAMPT (0.61) | EGFRFGFR1KDRMAPK10MAPK8 | |
| SCHEMBL22246675 | 0.77 | EGFR (0.64) | EGFRFGFR1KDRNPC1RAB9A | |
| SCHEMBL2860519 | 0.76 | ALKBH2 (0.71) | NPC1RAB9A | |
| SCHEMBL16976932 | 0.76 | EGFR (0.67) | EGFRFGFR1KDRMAPK10MAPK8 | |
| SCHEMBL22589703 | 0.76 | EGFR (0.63) | EGFRFGFR1KDRMAPK10MAPK8 | |
| SCHEMBL3794687 | 0.76 | NPC1 (1.00) | NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL18148273 | 0.76 | MAPK10 (0.85) | EGFRFGFR1KDRMAPK10MAPK8 | |
| SCHEMBL16802722 | 0.76 | MAPK10 (0.79) | MAPK10MAPK8MAPK9MAPK14 | |
| SCHEMBL16799878 | 0.76 | MAPK10 (1.00) | MAPK10MAPK8MAPK9MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024243025-A1 | NAPHTHYL-SUBSTITUTED PYRIDO[4,3-D]PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| EP-2379535-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | EGFR 1774/4885FGFR1 735/4885KDR 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.